CHICAGO, Aug. 30 Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the publication of a research paper in the journal Bioorganic and Medicinal Chemistry Letters that reports data using the Company's core triterpenoid platform technology in the discovery and development of new cancer therapeutic agents.
Advertisement
(Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)
Scientists at Advanced Life Sciences have identified a novel class of proprietary triterpenoids that cause cell death predominantly via the induction of apoptosis, which is a highly regulated process by which excessive or harmful cells are eliminated in order to maintain normal cell development and tissue homeostasis. Defects in the apoptotic cellular machinery and apoptosis inducing pathways often result in uncontrolled cell proliferation, tumor development and other malignant diseases. Resistance to apoptosis contributes greatly to the failure of cancer prevention and treatment. Thus, the triterpenoids discovered in this study may lead to important new therapeutic agents in the treatment of cancer. The article published online ahead of print can be found at http://dx.doi.org/10.1016/j.bmcl.2010.07.120
Advertisement
"Today's scientific publication demonstrating the potential of triterpenoids as potent anticancer agents, as well as the results we have generated showing the anti-infective activity of triterpenoids against a variety of viral and bacterial pathogens, underscore the therapeutic and commercial potential of this novel class of compounds and the productivity of our internal research and development capability," said Dr. Michael T. Flavin, chief executive officer of Advanced Life Sciences. "We look forward to advancing selected compounds into preclinical development and to sharing these results with potential corporate partners."
About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. In addition, the Company's earlier-stage pipeline is being enhanced through in-licensing activities, such as the recently announced collaboration with the University of British Columbia, and through an internal R&D program focused on discovering new treatments for cancer and infectious disease. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.
Forward-Looking Statements
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.
SOURCE Advanced Life Sciences Holdings, Inc.
